Topsy turvy times for industry’s mid and small cap stocks in the first quarter
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
US big biotechs lag in the opening quarter of the year
A look at sector share prices in the opening three months of 2019 reveals a resurgent big pharma and a strong showing from the world’s other large drug makers, with US…
Takeover flurry aside, progress of recent biotech floats underwhelms
A run of acquisitions of recent biotech IPOs is great news for investors who backed these companies, but the reality is that a large majority of fledgling drug stocks are…
Like the rest of biopharma investors, corporate VCs love oncology
Novartis scatters its VC seeds widely by leading rounds across a variety of therapy areas, although oncology still represents a big share of its funding activity.
Are the big corporate venture arms retreating?
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.
The sellside’s mid-term forecast: sunny with few hints of rain
Climbing consensus sales forecasts for 2022 suggest that last year equity analysts brushed off concerns about pricing restraints.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.